465 related articles for article (PubMed ID: 28511673)
41. Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies.
Farberg AS; Portela D; Sharma D; Kheterpal M
Am J Clin Dermatol; 2024 Jun; ():. PubMed ID: 38896403
[TBL] [Abstract][Full Text] [Related]
42. An update on the current and emerging pharmacotherapies for basal cell carcinomas.
Villani A; Scalvenzi M; Micali G; Martora F; Cillo F; Raia F; Potestio L
Expert Opin Pharmacother; 2023; 24(18):2143-2151. PubMed ID: 37963910
[TBL] [Abstract][Full Text] [Related]
43. New therapeutic developments for basal cell carcinoma.
Kunstfeld R; Nguyen VA
J Dtsch Dermatol Ges; 2023 Apr; 21(4):382-385. PubMed ID: 37070499
[TBL] [Abstract][Full Text] [Related]
44. A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma.
Odom D; Mladsi D; Purser M; Kaye JA; Palaka E; Charter A; Jensen JA; Sellami D
J Skin Cancer; 2017; 2017():6121760. PubMed ID: 28607774
[TBL] [Abstract][Full Text] [Related]
45. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.
Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M
Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959
[TBL] [Abstract][Full Text] [Related]
46. Japanese Dermatological Association guidelines: Outlines of Japanese clinical guidelines for basal cell carcinoma 2021.
Hoashi T; Ishikawa M; Uehara J; Oashi K; Maeda S; Kato J; Saruta H; Shichinohe R; Ohashi R; Nakamura Y; Koga H; Sugaya M;
J Dermatol; 2024 Apr; 51(4):e90-e105. PubMed ID: 38264942
[TBL] [Abstract][Full Text] [Related]
47. Locally Metastatic Basal Cell Carcinoma.
Porter HJ; Marghoob N; Dinehart M; Goldman G
Dermatol Surg; 2024 Jan; 50(1):101-102. PubMed ID: 37788225
[No Abstract] [Full Text] [Related]
48. Management of basal cell carcinoma with pulmonary metastasis.
Fordham SA; Shao EX; Banney L; Azer M; Dettrick A
BMJ Case Rep; 2023 Jan; 16(1):. PubMed ID: 36599494
[TBL] [Abstract][Full Text] [Related]
49. Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors.
Bossi P; Ascierto PA; Basset-Seguin N; Dreno B; Dummer R; Hauschild A; Mohr P; Kaufmann R; Pellacani G; Puig S; Moreno-Ramírez D; Robert C; Stratigos A; Gutzmer R; Queirolo P; Quaglino P; Peris K
Crit Rev Oncol Hematol; 2023 Sep; 189():104066. PubMed ID: 37442495
[TBL] [Abstract][Full Text] [Related]
50. New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib.
Koelblinger P; Lang R
Onco Targets Ther; 2018; 11():8327-8340. PubMed ID: 30568456
[TBL] [Abstract][Full Text] [Related]
51. Phase II Open-Label, Single-Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel in Patients with Basal Cell Carcinoma.
Kilgour JM; Shah A; Urman NM; Eichstadt S; Do HN; Bailey I; Mirza A; Li S; Oro AE; Aasi SZ; Sarin KY
Clin Cancer Res; 2021 Sep; 27(17):4717-4725. PubMed ID: 34362809
[TBL] [Abstract][Full Text] [Related]
52. Management of Locally Advanced Basal Cell Carcinoma with Sonic Hedgehog Pathway Targeted Therapy: A Case Report and Discussion.
Ferrin N; Edmond D; Jones R; McCahill LE
Case Rep Dermatol; 2024; 16(1):75-82. PubMed ID: 38481562
[TBL] [Abstract][Full Text] [Related]
53. Real-World Treatment Patterns and Outcomes Among Patients with Basal Cell Carcinoma Following First-Line Hedgehog Inhibitor Discontinuation.
Cowey L; Chen CI; Aguilar KM; Davies K; LaFontaine PR; Fury MG; Bowler T; Golozar A; Jalbert JJ
Dermatol Ther (Heidelb); 2022 May; 12(5):1211-1224. PubMed ID: 35507216
[TBL] [Abstract][Full Text] [Related]
54. Multicenter Retrospective Andalusian Study of the Use of Sonidegib for the Treatment of Local Advanced Basal Cell Carcinoma in Real Clinical Practice.
Ruiz-Villaverde R; Herrera-Acosta E; Ruiz de Casas A; Villegas-Romero IM; Moreno-Suárez FG; Vílchez-Márquez F; Galán-Gutiérrez M; Vázquez-Bayo MC; Cases-Mérida S; Almazán-Fernández FM
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685698
[TBL] [Abstract][Full Text] [Related]
55. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Fernández Orland A; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Yoo SY; Okoye E; Bassukas I; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Inocencio TJ; Chen CI; LaFontaine PR; Seebach F; Lowy I; Fury MG
J Am Acad Dermatol; 2024 Feb; 90(2):414-418. PubMed ID: 37839734
[No Abstract] [Full Text] [Related]
56. A multicenter real-world analysis of risk factors, therapeutics, and outcomes of patients with metastatic basal cell carcinoma.
Groover M; Gupta N; Granger E; Forrester VJ; Anstadt EJ; Su W; Heusinkveld L; Chen A; Lukens JN; Silk AW; Vidimos AT; Schoenfeld JD; Koyfman SA; Ruiz ES
J Am Acad Dermatol; 2024 Mar; 90(3):545-551. PubMed ID: 37949119
[TBL] [Abstract][Full Text] [Related]
57. Metastatic insidious super giant basal cell carcinoma.
Ahmed M; Muradashvili T; Soliman S; Ghaly M
BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760499
[TBL] [Abstract][Full Text] [Related]
58. Phase II Trial of
Wagner AJ; Ravi V; Riedel RF; Ganjoo K; Van Tine BA; Chugh R; Cranmer L; Gordon EM; Hornick JL; Du H; Ding L; Schmid AN; Navarro WH; Kwiatkowski DJ; Dickson MA
J Clin Oncol; 2024 May; 42(13):1472-1476. PubMed ID: 38427923
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
